The Korean government launched a new fund in 2011 to invest in innovative drug development projects. This program is driven by three missions: enabling partnerships among academia, government, and industry; establishing a successful model; and establishing an incubator for new drug development. The ultimate goal of this fund is to spur the development of ten global products. This session will examine Korean government regulation governing the biotechnology industry, comparing them with other countries, and discuss the impact of specific new regulations for biosimilar product development. Additionally, the session will provide the recent example of a Korean biotechonology company, Celltrion, which sucessfully undertook novel approaches to regulatory.
Ability Level: All
Session ID: 1984